Skip to content

NGNE: Held by 12 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Neurogene Inc. (NGNE)

Neurogene Inc.

NGNE

Held by 12 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

12 funds opened new positions. Next phase2 readout: Nov 2028. Short interest: 32.2% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

BiotechnologyCEO: Rachel L. McMinnIPO: 2014Website ↗

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

6.0/10

12 funds opened new positions●●

Recent insider sells only●●

Phase2 readout expected Nov 2028●●

Held by 12 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

12 specialist funds hold NGNE with a Phase 2 in 932 days (Neuronal Ceroid Lipofuscinosis CLN5)

+1 more upcoming catalyst

Avoro Capital Advisors EcoR1 Capital Redmile Group Rock Springs Capital Cormorant Asset Management Commodore Capital Baker Bros. Advisors RTW Investments Casdin Capital Driehaus Capital Deerfield Management Deep Track Capital

Fund Holdings

12 fund convergence

Avoro Capital Advisors

EcoR1 CapitalHeld 7Q

Redmile GroupHeld 7Q ↑

Rock Springs CapitalHeld 5Q

Cormorant Asset Management

Commodore Capital

Baker Bros. AdvisorsHeld 7Q ↑

RTW InvestmentsHeld 7Q ↑

Casdin CapitalHeld 7Q ↑

Driehaus CapitalHeld 7Q ↓

Deerfield Management

Deep Track Capital

Position history (shares)

Avoro Capital Advisors

2Q

EcoR1 Capital

7Q

Redmile Group

7Q

Rock Springs Capital

5Q

Cormorant Asset Management

2Q

Commodore Capital

5Q

Baker Bros. Advisors

7Q

RTW Investments

7Q

AI Signal

Signal: Deerfield Exit Amid Specialist Fund Convergence

Deerfield Management's exit from Neurogene contrasts sharply with 12 specialist funds accumulating positions, suggesting divergent risk assessments ahead of near-term catalysts (CLN5 Phase 2 readout Nov 2028, Rett Syndrome Phase 3 readout Dec 2029). The deep specialist convergence—including repeat genomics/rare disease investors (Cormorant, Casdin, Baker Bros., Avoro)—indicates high conviction in the platform, though Deerfield's departure warrants scrutiny on cash runway, clinical risk, or valuation concerns not captured in public filings.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Nov 14, 2025

$110.2M

7 funds

Feb 13, 2026

$0

0 funds

Feb 17, 2026

$134.3M

7 funds

Mar 16, 2026

$0

0 funds

-100% total institutional value over 13 quarters

Short Interest

High short interestSI rising 2 periods (+9.2%)

Short Shares

4.01M

Change

+3.3%

Days to Cover

26.2

% of Float

32.2%

Settlement

Apr 15, 2026

Short interest over 5 periods

Catalysts

Phase 2Q4 2028Neuronal Ceroid Lipofuscinosis CLN5NCT05228145

Phase 3Q4 2029Rett SyndromeNCT05898620

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/ARedmile Group9.9%Feb 17, 2026

SC 13G/AEcoR1 Capital9.9%Nov 14, 2025

SC 13G/ACommodore Capital3.0%Aug 14, 2025

SC 13G/ABaker Bros. Advisors7.0%Aug 14, 2025

SC 13GBaker Bros. Advisors9.9%May 15, 2025

SC 13G/ARTW Investments10.0%Feb 14, 2025

SC 13G/ARedmile Group9.9%Feb 14, 2025

SC 13G/ACasdin Capital8.7%Feb 14, 2025

SC 13GCommodore Capital5.4%Dec 11, 2024

SC 13GRTW Investments8.7%Nov 14, 2024

SC 13G/ACormorant Asset Management0.8%Nov 14, 2024

SC 13GCasdin Capital6.9%Nov 8, 2024

SC 13GCormorant Asset Management1.2%Feb 14, 2024

SC 13G/ARedmile Group8.1%Feb 14, 2024

SC 13GEcoR1 Capital10.0%Feb 14, 2024

SC 13G/ARedmile Group9.9%Dec 22, 2023

Recent Insider Activity

Jordan JulieChief Medical Officer

SaleMar 30, 2026

McMinn RachelChief Executive Officer

SaleMar 30, 2026

Start free trial for dollar amounts, share counts, and AI context.

Position Details

Avoro Capital AdvisorsEXITMar 16, 2026

Start free trialfor share counts, dollar values & AI analysis

89 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

Jordan JulieChief Medical OfficerSaleMar 30, 2026SEC Filing →

Shares: 828Value: $18,127.57Price: $21.89

NGNE - CMO Sale | Neutral Signal

Jordan Julie's $18.1K sale (828 shares, ~0.3% of typical CMO holdings) appears routine portfolio management rather than conviction-driven, given the modest size and lack of pattern context. Two meaningful catalysts remain 18+ months out (CLN5 phase 2 in Nov 2028, Rett syndrome phase 3 in Dec 2029), so timing doesn't suggest negative near-term expectations.

McMinn RachelChief Executive OfficerSaleMar 30, 2026SEC Filing →

Shares: 3,352Value: $73,995.06Price: $22.07

NGNE | CEO Selling Ahead of Catalysts

Rachel McMinn sold 3,352 shares (~$74K) at $22.07, representing modest portfolio diversification rather than conviction loss given two significant readouts looming (CLN5 Phase 2 in Nov 2028, Rett Phase 3 in Dec 2029). Sale timing is neutral—not clustering with previous insider activity or ahead of near-term milestones.

Also Held by These Funds

FATE3 funds RYTM3 funds NUVL3 funds PCVX3 funds RNA3 funds INSM3 funds ALNY3 funds ABCL2 funds

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

What Academic Research Says About Form 4 Insider Trading in Biotech Small Caps

8 min read

Biotech Penny Stocks with Insider Buying: What the Data Shows

7 min read

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Casdin Capital

7Q

Driehaus Capital

7Q

Deerfield Management

2Q